Skip to main content

RAD April 2023 Conference Abstracts and Posters

All accepted abstracts have been published in The British Journal of Dermatology, Volume 188, Issue Supplement 3, June 2023. You may access the publication at:

#396 - Rapid, substantial, and sustained reduction of itch in adults with atopic dermatitis applying ruxolitinib cream 1.5% (SCRATCH-AD)

Robert Bissonnette, Haobo Ren, Haq Nawaz, Philippa Halden, Etienne Saint-Cyr Proulx

#399 - Pooled safety analysis of lebrikizumab in patients with uncontrolled asthma from three randomized clinical trials

Jonathan Corren, Stanley J. Szefler, April W. Armstrong, Chitra R. Natalie, Ralph Zitnik, Fangyi Zhao, Kimberly Siu, Peter A. Lio, Robert J. Mourey (Non-author Presenter)

#400 - Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy

Emma Guttman-Yassky, David Rosmarin, Jacob P. Thyssen, Stephan Weidinger, Thomas Bieber, Hany ElMaraghy, Amber Reck Atwater, Evangeline Pierce, Chenjia Xu, Helena Agell Gimeno, Eric Simpson, Robert J Mourey (Non-author Presenter)

#401 - Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study

Amy Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan Irvine, Ana Pinto-Correia, Chitra R. Natalie, Evangeline Pierce, Sarah Reifeis, Renato Gontijo-Lima, Vivian Laquer, Stephan Weidinger, Nadine Isho (Non-author Presenter)

#402 - Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials

Adelaide Hebert, Carsten Flohr, H. Chih-ho Hong, Alan Irvine, Evangeline Pierce, Hany ElMaraghy, Wen Xu, Sreekumar Pillai, Zach Dawson, Elaine Siegfried, Stephan Weidinger

#403 - Achievement of minimal disease activity is associated with improvements in symptoms, quality of life, and treatment satisfaction in patients with atopic dermatitis

Jonathan I. Silverberg, Melinda J. Gooderham, Norito Katoh, Valeria Aoki, Andrew E. Pink, Yousef Binamer, Wan-Ju Lee, Brian M. Calimlim, Shiyu Zhang, Amy Gamelli, Sarah Ofori, Andreas Wollenberg

#405 - Understanding patient experience and factors influencing patient preference in thetreatment of moderate-to-severe atopic dermatitis through in-depth qualitative patient interviews

Steven R. Feldman, Annie Guerin, Marjolaine Gauthier-Loiselle, Ami J. Claxton, Yan Meng, Nisha C. Hazra, Sanjeev Balu

#406 - Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial

Amy Paller, John E. Jett, Adelaide Hebert, Philip M. Brown, Victoria Butners, Nancy Fitzgerald, Marta Delgado, Mercedes E. Gonzalez, Stephen C. Piscitelli

#408 - Dupilumab treatment in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial

Eric L. Simpson, Jonathan I. Silverberg, Margitta Worm, Golara Honari, Koji Masuda, Ewa Sygula, Jennifer Maloney, Leda P. Mannent, Jing Xiao, Ariane Dubost-Brama, Ashish Bansal

#409 - Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the measure up 1, measure up 2, and ad up phase 3 clinical trials at 52 weeks

Amy S. Paller, Pedro Mendes-Bastos, Lawrence F. Eichenfield, Weily Soong, Peter Lio, Vimal H. Prajapati, Andrew M. Platt, Eliza Raymundo, John Liu, Barry Ladizinski, Jacob P. Thyssen

Page 3 of 6
Results 21 - 30 of 60